The relationship of antimullerian hormone with severity of clinical symptoms in polycystic ovary syndrome.

Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in around 6-8% of women in their reproductive years. The measurement of Anti-Müllerian Hormone (AMH) holds particular promise in discerning both the diagnosis and the extent of severity in PCOS cases. This study aims to evaluate the effectiveness of using AMH as a potential tool for identifying and diagnosing the severity of clinical aspects associated with the syndrome.

Materials and methods: A retrospective analysis was performed on 309 female patients who presented for consultation at our hospital's gynecology outpatient clinic and were diagnosed with PCOS based on the Rotterdam criteria, between January 2018 and March 2022. Data were extracted from the hospital database and systematically assessed. Patients were divided into two groups based on the mean AMH level of 7.5 ng/mL, allowing comparison between higher and lower AMH subgroups. Clinical symptoms and findings were assessed based on AMH values.

Results: A statistically significant difference was observed between groups for the mean levels of total testosterone, androstenedione, free androgen index, luteinizing hormone, and follicle-stimulating hormone (p < 0.05). Additionally, a statistically significant difference was noted between AMH groups and the presence of oligomenorrhea (p < 0.05).

Conclusion: Even at the higher end of the spectrum, AMH retains significant value in determining the clinical aspects of PCOS.